title: Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.
abstract: OBJECTIVE
  The aim of this study is to evaluate the efficacy of intraperitoneal cisplatin as consolidation treatment in epithelian ovarian cancer patients with complete pathologic response following front-line platin-based chemotherapy.
  
  
  METHODS
  Thirty patients who had no evidence of disease as assessed by second-look laparotomy following chemotherapy for stage III epithelial ovarian cancer were given three courses of intraperitoneal cisplatin (100 mg/m(2)) with three weekly intervals as consolidation therapy.
  
  
  RESULTS
  Median age was 50 years. After a median follow-up period of 37 months, 16 patients are being followed with no evidence of disease. Eleven patients developed recurrent disease. Median disease-free survival was 50 months. Median overall survival is not reached. WHO grades 3-4 toxicity criteria were emesis in 19 patients (63.3%), abdominal pain in 5 (16.7%) and nephrotoxicity in 2 (6.7%) patients. Catheter-related complications were infection/peritonitis in one and catheter malfunction in one patient. There were no serious hematologic side effects that required transfusions or caused treatment delays. None of the patients developed serious neurologic toxicity. Treatment had to be stopped early in four patients who refused further treatment due to abdominal pain, nausea ::and vomiting. Dose reductions were required in five patients.
  
  
  CONCLUSIONS
  Our results suggest that intraperitoneal cisplatin is a feasible regimen that may provide a favorable outcome in terms of progression-free survival in patients with a complete pathologic response following front-line treatment for ovarian cancer. Further randomized trials are required to evaluate the role of consolidation treatment in this setting.
authors.affiliation: Istanbul University Institute of Oncology, Istanbul, Turkey.
authors.forename: Erkan
authors.initials: E
authors.lastname: Topuz
authors.forename: Yesim
authors.initials: Y
authors.lastname: Eralp
authors.forename: Sezer
authors.initials: S
authors.lastname: Saglam
authors.forename: Pinar
authors.initials: P
authors.lastname: Saip
authors.forename: Adnan
authors.initials: A
authors.lastname: Aydiner
authors.forename: Sinan
authors.initials: S
authors.lastname: Berkman
authors.forename: Ekrem
authors.initials: E
authors.lastname: Yavuz
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007813:Laparotomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D024162:Second-Look Surgery
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin